Keyword Search
Legend:
CC = Vancouver Convention Centre F = Fairmont Waterfront Vancouver
* = applied session ! = JSM meeting theme
|
Keyword Search Criteria: Phase I returned 38 record(s)
|
|
Monday, 07/30/2018
|
Dose Finding Methods Using Two Endpoints in Early Clinical Studies
Kyounghwa Bae, Janssen Research & Development, LLC; Zhentao Tong, North Carolina State University ; Vladimir Dragalin, Janssen R&D
|
A Bayesian Logistic Model with Covariate to Identify Optimal Dose for Heterogeneous Population in Phase I Oncology Trial
Xin Wei, Celgene Corporation; Michael Branson, celgene corporation
8:50 AM
|
A Bayesian Phase I/II Trial Design for Immunotherapy
Suyu Liu, MD Anderson Cancer Center; Beibei Guo, Louisiana State University; Ying Yuan, University of Texas M.D. Anderson Cancer Center
10:35 AM
|
Dose Finding Methods Using Two Endpoints in Early Clinical Studies
Kyounghwa Bae, Janssen Research & Development, LLC; Zhentao Tong, North Carolina State University ; Vladimir Dragalin, Janssen R&D
11:55 AM
|
Extension of Bayesian Logistic Regression Model (BLRM) for Dose Timing Selection in Oncology Phase I Combination Studies
Yiyun Zhang, Novartis; Nigel Yateman, Novartis; Fang Xiang, Novartis; Lan Yi, Novartis; Kapildeb Sen, Novartis; Beat Neuenschwander, Novartis
2:05 PM
|
Phase I Designs That Allow for Uncertainty in the Attribution of Adverse Events
Alexia Iasonos, Memorial Sloan Kettering Cancer Center; John O'Quigley, Universit'e Pierre et Marie Curie,
2:35 PM
|
GBM AGILE: a Phase II/III Platform Design with Signature Identification
Todd Graves, Berry Consultants LLC; Donald A Berry, Berry Consultants and M.D. Anderson Cancer Center; Jason Connor, ConfluenceStat LLC
2:45 PM
|
Improvements to the Escalation with Overdose Control Design and a Comparison with the Restricted Continual Reassessment Method
Lingyun Ji, University of Southern California; Richard Sposto, University of Southern California; Juan Pablo Lewinger, University of Southern California; Mark Krailo, University of Southern California; David Conti, University of Southern California; Susan Groshen, University of Southern California; Shahab Asgharzadeh, University of Southern California
3:00 PM
|
Bayesian Isotonic Optimal Dose Design for Phase I/II Clinical Trials with Ordered Groups
Xiaoqiang Xue
3:05 PM
|
|
Tuesday, 07/31/2018
|
Use of Modified Risk Function in Drug Intervention Planning
Myung Shin Sim, UCLA
|
A Bayesian Adaptive Design in Cancer Phase I/II Trials with Drug Combinations Using Escalation with Overdose Control (EWOC) and Adaptive Randomization
Sungjin Kim, Cedars-Sinai Medical Center; José L. Jiménez, Politecnico di Torino; Mourad Tighiouart, Cedars-Sinai Medical Center
|
Improvements to the Escalation with Overdose Control Design and a Comparison with the Restricted Continual Reassessment Method
Lingyun Ji, University of Southern California; Richard Sposto, University of Southern California; Juan Pablo Lewinger, University of Southern California; Mark Krailo, University of Southern California; David Conti, University of Southern California; Susan Groshen, University of Southern California; Shahab Asgharzadeh, University of Southern California
|
Phase I Designs That Allow for Uncertainty in the Attribution of Adverse Events
Alexia Iasonos, Memorial Sloan Kettering Cancer Center; John O'Quigley, Universit'e Pierre et Marie Curie,
|
A Confirmatory Basket Trial Design for Multiple Tumor Types Based on Conditional Power
Huiling Li; Jianming Wang, Celgene Corporation; Yeongjin Gwon, University of Connecticut; Xiaolong Luo, Celgene Corporation
9:05 AM
|
Reversals in Early Phase Dose Finding Trials
Bethany Horton, University of Virginia; John O'Quigley, Universit'e Pierre et Marie Curie, ; Mark Conaway, University of Virginia
10:35 AM
|
A Note on Phase II Single-Arm Two-Stage Designs for Safety
Seongho Kim, Wayne State University; Weng Kee Wong, UCLA
10:50 AM
|
Biomarker-Defined Subgroup Selection Adaptive Design for Phase III Confirmatory Trial
Rui Tang, Shire; Xiaoye Ma, University of Minnesota; Hui Yang, Amgen Inc.
11:50 AM
|
AAA: Triple-Adaptive Bayesian Designs for the Identification of Optimal Dose Combinations in Dual-Agent Dose-Finding Trials
Jiaying Lyu, University of Chicago; Fudan University; Yuan Ji, NorthShore Univ. HealthSystem / The University of Chicago
11:55 AM
|
Dose Finding Model Selection in Oncology Combination Therapy
Lixia Pei, Janssen Pharmaceuticals ; Yichen Guo, Harvard University; Kevin Liu, Janssen Pharmaceuticals
2:20 PM
|
|
Wednesday, 08/01/2018
|
A Stagewise Prognostic Control Predictive Approach (SPCPA) for Subgroup Identification and Its Application in a Phase II Study
Wanying Li, Gilead Sciences; Wangshu Zhang, Gilead Sciences; Lovely Goyal, Gilead Sciences; Yuanyuan Xiao, Gilead Sciences
|
Single Item Analysis of Patient-Reported Outcome Measures in a Phase III Randomized Controlled Trial
Stacie Hudgens, Clinical Outcome Solutions; Lysbeth Floden, Clinical Outcome Solutions
|
A Two-Stage, Phase II Clinical Trial Design with Nested Criteria for Early Stopping and Efficacy: Expected Trial Duration and Tools for Planning
Michelle DeVeaux, Regeneron Pharmaceuticals; Michael John Kane, Yale University; Daniel Zelterman, Yale University
|
A Stagewise Prognostic Control Predictive Approach (SPCPA) for Subgroup Identification and Its Application in a Phase II Study
Wanying Li, Gilead Sciences; Wangshu Zhang, Gilead Sciences; Lovely Goyal, Gilead Sciences; Yuanyuan Xiao, Gilead Sciences
8:35 AM
|
Single Item Analysis of Patient-Reported Outcome Measures in a Phase III Randomized Controlled Trial
Stacie Hudgens, Clinical Outcome Solutions; Lysbeth Floden, Clinical Outcome Solutions
9:00 AM
|
Controlling the Family-Wise Type I Error Rate in a Phase II POC Trial of the Merck Pneumococcal Vaccine Program: An Application of the Hochberg Approach
Jianing Li, Merck Research Lab
9:35 AM
|
A Biomarker-Directed Phase 2 Oncology Umbrella Trial to Target Combination Therapy in NSCLC
Hua Ma, Merck; Robin Mogg, Merck Research Laboratories
9:35 AM
|
A Two-Stage, Phase II Clinical Trial Design with Nested Criteria for Early Stopping and Efficacy: Expected Trial Duration and Tools for Planning
Michelle DeVeaux, Regeneron Pharmaceuticals; Michael John Kane, Yale University; Daniel Zelterman, Yale University
9:50 AM
|
Evaluating the Statistical Properties of Bayesian Basket Trial Designs
Kristen May Cunanan, Memorial Sloan Kettering Cancer Center; Alexia Iasonos, Memorial Sloan Kettering Cancer Center; Ronglai Shen, Memorial Sloan-Kettering Cancer Center; Colin B Begg, Memorial Sloan Kettering Cancer Center; Mithat Gonen, Memorial Sloan Kettering Cancer Center
10:35 AM
|
Novel Model-Assisted Designs for Phase I Drug Combination Trials
Ruitao Lin, MD Anderson Cancer Center
10:35 AM
|
Adaptive Dose Finding in Oncology Phase I-II Studies with Consideration of Tolerability and Efficacy
Rachael Liu, Takeda Pharmaceuticals ; Ling Wang, Takeda; David Sinclair, Google; Jianchang Lin, Takeda Pharmaceuticals
11:35 AM
|
AAA: Triple-Adaptive Bayesian Designs for the Identification of Optimal Dose Combinations in Dual-Agent Dose-Finding Trials
Yuan Ji, NorthShore Univ. HealthSystem / The University of Chicago; Jiaying Lyu, Fudan Universtiy
11:35 AM
|
How the ICH E9 Addendum Influenced a Phase III Clinical Trial with a Radiographic Endpoint
Ruvie Martin, Novartis Pharmaceuticals
11:50 AM
|
|
Thursday, 08/02/2018
|
A Bayesian Adaptive Phase 1/2 Design of Cisplatin and Cabazitaxel in Prostate Cancer with Visceral Metastasis
Mourad Tighiouart, Cedars-Sinai Medical Center
10:35 AM
|
Bias-Corrected Estimation of Treatment Effects in Biomarker-Based Adaptive Subgroup Analysis: New Approach Based on Randomized Tests with Smooth Rejection Function
Kiichiro Toyoizumi, Shionogi Inc.; Shigeyuki Matsui, Nagoya University
11:05 AM
|
Shewhart-Type Charts in Some Nonstandard Situations: Phase I and Phase II
Yuhui Yao, University of Alabama; Subhabrata Chakraborti, University of Alabama
11:05 AM
|
Adjustment for Phase II S^2 Chart Control Limits Based on Tolerance Intervals
Martin Guillermo Cornejo Sarmiento, Pontifical Catholic University of Rio de Janeiro; Subhabrata Chakraborti, University of Alabama; Eugenio Kahn Epprecht, Pontifical Catholic University of Rio de Janeiro
11:20 AM
|
Biomarker Guided Phase II Two-Stage Design for Targeted Therapy
Zheyu Wang, Johns Hopkins University; Fujun Wang, Medimmune; Chenguang Wang, Johns Hopkins University; Gary Rosner, Johns Hopkins University; Jianliang Zhang, Medimmune; Hao Wang, Johns Hopkins University; Li Shi, Medimmune
11:25 AM
|
|
|
